Get the Stockscreener App
36.27
0.68%
-0.25
Sarepta Therapeutics Inc stock is traded at $36.27, with a volume of 6.61M.
It is down -0.68% in the last 24 hours and down -34.82% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$36.52
Open:
$37.32
24h Volume:
6.61M
Relative Volume:
2.51
Market Cap:
$6.24B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
23.55
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
-42.89%
1M Performance:
-34.82%
6M Performance:
-70.18%
1Y Performance:
-72.59%
1-Day Range:
$35.93
$39.66
1-Week Range:
$35.46
$64.80
52-Week Range:
$35.46
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
36.27 | 6.24B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
These 3 Biotech Picks Can Combat Sarepta Losses After Unexpected Death - TheStreet Pro
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ... - Bluefield Daily Telegraph
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance
Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut - Bloomberg.com
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference | SRPT Stock News - GuruFocus
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
Sarepta Therapeutics (SRPT) Faces Investment Rating Downgrade - GuruFocus
Sarepta price target lowered to $125 from $183 at Needham - Yahoo Finance
Sarepta Therapeutics (SRPT) Price Target Lowered by Wells Fargo | SRPT Stock News - GuruFocus
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating - marketscreener.com
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot - simplywall.st
Evercore ISI cuts Sarepta stock rating, slashes price target - Investing.com
Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sarepta (SRPT) Downgraded by Evercore ISI with New Price Target | SRPT Stock News - GuruFocus
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - Insider Monkey
Beware of Sarepta, CRISPR Therapeutics, and More - Baystreet.ca
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges - TipRanks
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment - insights.citeline.com
Some unshod by Prasad nod as CBER change socks stocks - BioWorld MedTech
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance
Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire. - Barron's
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga
BMO Capital cuts Sarepta stock target to $120, maintains Outperform - Investing.com
Cantor Fitzgerald cuts Sarepta stock target to $81 - Investing.com
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (NASDAQ:SRPT) - Seeking Alpha
TD Cowen cuts Sarepta stock target, maintains Buy rating - Investing.com
Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire - BioPharma Dive
Sarepta (SRPT) Target Price Lowered by Needham Amid Leadership Change Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by Piper Sandler | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target but Maintains Rating | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Revised by Cantor Fitzgerald | SRPT Stock News - GuruFocus
Sarepta (SRPT) Price Target Cut by RBC Capital Amid Elevidys Challenges | SRPT Stock News - GuruFocus
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Sarepta Therapeutics (SRPT) Sees Price Target Reduced by Analyst | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results - Benzinga
Sarepta Therapeutics (SRPT) Price Target Lowered by Needham Analyst | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Call Transcript - Insider Monkey
Sarepta (SRPT) Faces Price Target Reduction Amid Revenue Challenges | SRPT Stock News - GuruFocus
Sarepta stock target cut to $40 by H.C. Wainwright on slow sales - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Sarepta (SRPT) Target Price Reduced Amid Regulatory Concerns | SRPT Stock News - GuruFocus
Guggenheim Adjusts Sarepta (SRPT) Price Target Amid Uncertainty | SRPT Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; Sarepta Therapeutics, OneStream Lag - Barron's
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales - Yahoo Finance
Sarepta (SRPT) Price Target Reduced by Morgan Stanley Amid Elevidys Sales Challenges | SRPT Stock News - GuruFocus
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):